Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

NCT05704738 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05704738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2023
Completion date
November 25, 2025
Enrollment
532 (actual)
Sites
246

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis